Log In Sign up
The largest database of trusted experimental protocols

Mek inhibitor u0126

Manufactured by Selleck Chemicals
Visit Supplier
Sourced in United States

MEK inhibitor U0126 is a chemical compound that acts as a selective inhibitor of the mitogen-activated protein kinase kinase (MEK) enzymes. It primarily blocks the activity of the MEK1 and MEK2 proteins, which are involved in the regulation of the extracellular signal-regulated kinase (ERK) signaling pathway.

Automatically generated - may contain errors

Lab products found in correlation

Galactose, by Merck Group (2 mentions) Pd153035, by Selleck Chemicals (2 mentions) Ag1478, by Selleck Chemicals (2 mentions) Lipofectamine 2000, by Thermo Fisher Scientific (2 mentions)

Spelling variants of this product

U0126 (219 citations) MEK inhibitor (2 citations)

3 protocols using mek inhibitor u0126

1

ITLN1 Silencing in BEAS-2B Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
BEAS-2B cells (CRL-9609, American Type Culture Collection) were cultured in DMEM/high glucose (HyClone) in 6-well plates. When cells were 90% confluent, 4 μg hITLN1 shRNA or scrambled shRNA plasmid in 250 μl of Opti-MEMI medium was mixed with 10 μl lipofectamine 2000 (Invitrogen) diluted in 240 μl of medium and added to each well. Six hours later, the media were substituted with DMEM with or without HDM (25 μg/ml; Greer Lab). At the indicated time points, cells were harvested for quantitative RT-PCR and Western blotting, and the media were collected for ELISA. The sequence of ITLN1 shRNA (sense strand) was: 5′-GCATCTTATTACTCACCCTATCTCGAGATAGGGTGAGTAATAAGATGC-3′. The sequence of scrambled shRNA (sense strand) was: 5′-GCCCATTCTTATCATACTCATCTCGAGATGAGTATGATAAGAATGGGC-3′.
For inhibition of ITLN with galactose, galactose (Sigma) was added to the medium (final concentration 30 mM) 1 h before HDM stimulation. EGFR inhibitor PD153035 (Selleck, final concentration 5μM) and AG1478 (Selleck, final concentration 10μM), and MEK inhibitor U0126 (Selleck, final concentration 10μM) were added to the medium 1 h before HDM stimulation.
Yi L., Cheng D., Zhang K., Huo X., Mo Y., Shi H., Di H., Zou Y., Zhang H., Zhao J., Xu Y., Erle D.J, & Zhen G. (2017). Intelectin contributes to allergen-induced IL-25, IL-33 and TSLP expression and type 2 response in asthma and atopic dermatitis. Mucosal immunology, 10(6), 1491-1503.
+ Open protocol
+ Expand
2

ITLN1 Silencing in BEAS-2B Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
BEAS-2B cells (CRL-9609, American Type Culture Collection) were cultured in DMEM/high glucose (HyClone) in 6-well plates. When cells were 90% confluent, 4 μg hITLN1 shRNA or scrambled shRNA plasmid in 250 μl of Opti-MEMI medium was mixed with 10 μl lipofectamine 2000 (Invitrogen) diluted in 240 μl of medium and added to each well. Six hours later, the media were substituted with DMEM with or without HDM (25 μg/ml; Greer Lab). At the indicated time points, cells were harvested for quantitative RT-PCR and Western blotting, and the media were collected for ELISA. The sequence of ITLN1 shRNA (sense strand) was: 5′-GCATCTTATTACTCACCCTATCTCGAGATAGGGTGAGTAATAAGATGC-3′. The sequence of scrambled shRNA (sense strand) was: 5′-GCCCATTCTTATCATACTCATCTCGAGATGAGTATGATAAGAATGGGC-3′.
For inhibition of ITLN with galactose, galactose (Sigma) was added to the medium (final concentration 30 mM) 1 h before HDM stimulation. EGFR inhibitor PD153035 (Selleck, final concentration 5μM) and AG1478 (Selleck, final concentration 10μM), and MEK inhibitor U0126 (Selleck, final concentration 10μM) were added to the medium 1 h before HDM stimulation.
Yi L., Cheng D., Zhang K., Huo X., Mo Y., Shi H., Di H., Zou Y., Zhang H., Zhao J., Xu Y., Erle D.J, & Zhen G. (2017). Intelectin contributes to allergen-induced IL-25, IL-33 and TSLP expression and type 2 response in asthma and atopic dermatitis. Mucosal immunology, 10(6), 1491-1503.
+ Open protocol
+ Expand
3

Silencing circZCCHC2 and miR-1200 Modulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The shRNA that specifically targets circZCCHC2 was synthesized by GenePharma (Shanghai, China) and then inserted into the pcDNA3.1-GFP vector. To construct the circZCCHC2 overexpression vector, the full length human hsa_circ_0000854 was inserted into the C-1170 vector (LandM, Guangzhou, China), which contains a circular frame. Puromycin administration (Yeasen Biotech) was used to screen stable cell lines. The si-TPR, miR-1200 mimics, and miR-1200 inhibitor were purchased from GenePharma in Shanghai, China (Table S2). Transfection of plasmids, siRNA, or miRNA mimics or inhibitors was performed using GoldenTran-DR transfection reagent (Changchun Golden Transfer Science and Technology Co., Ltd., China) according to the manufacturer’s instructions. MEK inhibitor U0126 (Selleck, USA) used in the study were prepared by dimethyl sulfoxide (DMSO). Final concentration used for cell experiments was 5 μM and the treatment time lasted 24 h.
Zhang F., Wei D., Xie S., Ren L., Qiao S., Li L., Ji J, & Fan Z. (2024). CircZCCHC2 decreases pirarubicin sensitivity and promotes triple-negative breast cancer development via the miR-1200/TPR axis. iScience, 27(3), 109057.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!